Palisade Bio, Inc.
(NASDAQ : CUR)

( )
CUR After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 0.72%52.850.9%$1374.69m
JNJJohnson & Johnson 1.40%179.460.7%$1371.52m
BMYBristol-Myers Squibb Co. 0.63%76.671.0%$1204.82m
MRKMerck & Co., Inc. 0.45%93.980.7%$1144.89m
ABBVAbbVie, Inc. -1.98%148.021.9%$1115.58m
LLYEli Lilly & Co. 1.25%302.571.1%$903.32m
AZNAstraZeneca Plc 0.30%66.411.0%$519.21m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.66%142.970.0%$461.53m
VERUVeru, Inc. 5.53%14.120.0%$336.28m
NVSNovartis AG 1.45%90.720.2%$254.85m
GSKGlaxoSmithKline Plc 0.53%44.760.2%$244.47m
HZNPHorizon Therapeutics Plc -3.29%87.385.4%$193.81m
NVONovo Nordisk A/S 0.07%107.830.1%$190.87m
SGENSeagen Inc. -0.22%139.345.7%$181.36m
VTRSViatris, Inc. -1.44%11.630.0%$163.74m

Company Profile

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.